Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 4, 2016, Pages 1046-1050

  Gubavu, Camelia ^a   Prazuck, Thierry ^a   Niang, Mohamadou ^a   Buret, Jennifer ^a   Mille, Catherine ^a   Guinard, Jérôme ^a   Avettand Fènoël, Véronique ^b,c   Hocqueloux, Laurent ^a  

^a Centre Hospitalier Régional   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CD4 ANTIGEN; CREATINE KINASE; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; LAMIVUDINE; MARAVIROC; RILPIVIRINE; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD; ANTIVIRAL RESISTANCE; DRUG EFFECTS; FOLLOW UP; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; MUTATION; RETREATMENT; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; RETREATMENT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84964337081     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv430     Document Type: Article

References (16)

1. Günthard HF, Aberg JA, Eron JJ et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312: 410-25.
2. Prise en Charge Mé dicale des Personnes Vivant avec le VIH. Recommandations du Groupe d'Experts. Rapport 2013. http://www.sante.gouv.fr/IMG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf.
3. Hasse B, Ledergerber B, Furrer H et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53: 1130-9.
4. Greig SL, Deeks ED. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Drugs 2015; 75: 503-14.
5. Perez-Molina JA, Rubio R, Rivero A et al. Dual treatment with atazanavirritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48. week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis 2015; 15: 775-84.
6. Arribas J, Girard P-M, Paton N et al. Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials. J Int AIDS Soc 2014; 17: 19788.
7. Clotet B, Feinberg J, van Lunzen J et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383: 2222-31.
8. Lennox JL, Landovitz RJ, Ribaudo HJ et al. Efficacy and tolerability of 3. nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 2014; 161: 461-71.
9. Cahn P, Pozniak AL, Mingrone H et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382: 700-8.
10. Fourati S, Charpentier C, Amiel C et al. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. J Antimicrob Chemother 2015; 70: 1507-12.
11. Min S, Sloan L, DeJesus E et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011; 25: 1737-45.
12. Castagna A, Maggiolo F, Penco G et al. Dolutegravir in antiretroviralexperienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 210: 354-62.
13. Wainberg MA, Han Y-S. Will drug resistance against dolutegravir in initial therapy ever occur? Front Pharmacol 2015; 6: 90.
14. Rojas J, Blanco JL, Lonca M et al. Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression: a 24-week pilot study. In: Abstracts of the Fifteenth European AIDS Conference, Barcelona, 2015. Abstract LBPS4/2. European AIDS Clinical Society, Brussels, Belgium.
15. Katlama C, Soulié C, Blanc C et al. Dolutegravir monotherapy in HIV-infected patients with suppressed HIV viremia. In: Abstracts of the Fifteenth European AIDS Conference, Barcelona, 2015. Abstract PS4/4. European AIDS Clinical Society, Brussels, Belgium.
16. Colasanti J, Marconi VC, Taiwo B. Antiretroviral reduction: is it time to rethink the unthinkable? AIDS 2014; 28: 943-7.